Oppenheimer on Acrivon Therapeutics Inc (ACRV): 'all-comer' approach comes with risks, but necessary
Tweet Send to a Friend
Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $8.00 price target on Acrivon Therapeutics Inc (NASDAQ: ACRV)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
